Compare Bath & Body Works Inc (BBWI) vs Cronos Group Inc (CRON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bath & Body Works Inc vs Cronos Group Inc — how do they compare? Bath & Body Works Inc trades at $18.9 (market cap $3.81B), while Cronos Group Inc trades at $3.08 (market cap $1.14B). The key difference: Bath & Body Works Inc is far larger — about 3.3× Cronos Group Inc's market cap, and Bath & Body Works Inc pays a 4.24% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| BBWI | CRON | |
|---|---|---|
Market Cap | $3.81B | $1.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.87 | $3.27 |
52-Week Low | $14.85 | $2.30 |
Enterprise Value | $7.70B | $341.13M |
Dividend Yield | 4.24% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
